Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Head & Neck 1

Conditions

Breast Neoplasms 75Neoplasms 15Neoplasm Metastasis 9Advanced Breast Cancer 5Neoplasms by Site 3Breast Diseases 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Patient Compliance 2Ovarian Neoplasms 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Recurrence 1Quality of Life 1Osteoporosis 1Multiple Endocrine Neoplasia Type 1 1Low Grade Serous Ovarian Cancer 1Lethal Congenital Contracture Syndrome 2 1Joint Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Cancer Metastatic 1Bone Diseases, Metabolic 1Bone Density 1Arthralgia 1Advanced Metastatic Breast Cancer 1

Interventions

Paclitaxel 113Carboplatin 99Bevacizumab 59pembrolizumab 56liposomal doxorubicin 56Gemcitabine 42olaparib 39Topotecan 33niraparib 29Nivolumab 21Cisplatin 21Doxorubicin 17Cyclophosphamide 171-dodecylpyridoxal 16Drug Therapy 15Docetaxel 15avelumab 13Fulvestrant 11oregovomab 10Oxaliplatin 10rucaparib 9fludarabine 9Injections 9Fluorouracil 9veliparib 8mirvetuximab soravtansine 8atezolizumab 8Cetuximab 8fluzoparib 7cemiplimab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Neoplasms × Anastrozole × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT02476955 2020-09-30

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Terminated
41 enrolled
BreastGynecologic

Uterine Cervical Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡